Abstracts tagged "Antimalarial drugs and systemic lupus erythematosus (SLE)"

Abstract Number: 1590 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Increases the Risk for Severe Brady-Arrhythmias in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Jiandong Su⁴ and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Severe brady-arrhythmias [complete atrioventricular block (cAVB) and sick sinus syndrome (SSS)] have a prevalence of 0.04% and 0.8% in the general population respectively and…
Abstract Number: 1592 • 2017 ACR/ARHP Annual Meeting
Antimalarial-Induced Cardiomyopathy in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Mery Deeb², Dafna D Gladman³, Paula Harvey⁴, Shadi Akhtari⁴, Susanna Mak⁵, Jagdish Butany⁶ and Murray Urowitz⁷, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁵Mecklinger Family and Posluns Family  Cardiac Catheterization Research Laboratory, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada, ⁷Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarials (AM) are currently recommended for the management of all patients with systemic lupus erythematosus (SLE) without specific contra-indications. Their main adverse effect is…
Abstract Number: 2612 • 2017 ACR/ARHP Annual Meeting
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record
J.B. Boone, Wendy Xiong, Cecilia P. Chung, Leslie Crofford and April Barnado, Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antimalarials (AMs) reduce disease activity and improve survival in patients with systemic lupus erythematosus (SLE) and are recommended regardless of disease severity. Prior studies…
Abstract Number: 2617 • 2017 ACR/ARHP Annual Meeting
Electrocardiogram Abnormalities Related to Antimalarials in Systemic Lupus Erythematosus
Taneisha McGhie¹, Paula Harvey², Jiandong Su¹, Nicole Anderson³, George A. Tomlinson⁴ and Zahi Touma⁵, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada
Background/Purpose: Anti-malarials (AM), such as hydroxychloroquine (HCQ) and chloroquine (CQ), have long been used for the treatment of systemic lupus erythematosus (SLE). However, despite their…
Abstract Number: 754 • 2016 ACR/ARHP Annual Meeting
The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…
Abstract Number: 1793 • 2015 ACR/ARHP Annual Meeting
Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Elevated muscle enzymes in the course of systemic lupus erythematosus (SLE) usually represent active myositis or drug-related toxicity. Lipid-lowering agents and, less frequently, antimalarials…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].